CriticalClass III antiarrhythmic×Second-generation systemic triazole antifungal
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises dronedarone, and ketoconazole 200 mg a day, a strong inhibitor of this enzyme, increased dronedarone levels 17-fold (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). Posaconazole is also a strong CYP3A4 inhibitor and can markedly increase exposure to drugs that this enzyme metabolises, but the documents give no figures for the combination with dronedarone (posaconazole SmPC, EMA, and posaconazole label, US Food and Drug Administration, FDA). Dronedarone prolongs the QT interval in a concentration-dependent way (dronedarone label, FDA), and posaconazole must not be given with drugs that are CYP3A4 substrates and prolong the QT interval (posaconazole SmPC and label, EMA and FDA). Some azoles, including posaconazole, have been associated with QT prolongation, and cases of torsade de pointes have been reported in people taking posaconazole. However, posaconazole did not increase the mean heart-rate-corrected QT interval in healthy volunteers (FDA). In the other direction, dronedarone strongly inhibits P-glycoprotein. In vitro, posaconazole is a substrate of this efflux transporter, and P-glycoprotein inhibitors may increase posaconazole levels (dronedarone and posaconazole SmPCs, EMA).
Symptoms
The main risk is QT prolongation and torsade de pointes ventricular tachycardia (dronedarone and posaconazole labels, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Uncommon effects of posaconazole include long QT syndrome, ECG abnormalities, palpitations, slow and fast heart rate. Rare effects include torsade de pointes, ventricular tachycardia, cardiorespiratory arrest and sudden death (posaconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). Dronedarone can slow the heart rate and cause or worsen heart failure, with weight gain, swelling and increasing shortness of breath (dronedarone SmPC, EMA). Both drugs can harm the liver, and the dronedarone SmPC lists persistent abdominal pain, loss of appetite, nausea, vomiting, fever, malaise, tiredness, jaundice, dark urine and itching as warning signs (dronedarone and posaconazole SmPCs, EMA).
Management
The combination is contraindicated. The European dronedarone summary of product characteristics (SmPC) names posaconazole among the strong CYP3A4 inhibitors that must not be used with dronedarone (dronedarone SmPC, European Medicines Agency, EMA). The US dronedarone label contraindicates all strong CYP3A inhibitors and says to stop them before starting dronedarone. According to its own US label, posaconazole is a strong CYP3A4 inhibitor (dronedarone and posaconazole labels, US Food and Drug Administration, FDA). On the posaconazole side, the US label contraindicates posaconazole with CYP3A4 substrates that prolong the QT interval, and the European SmPC says not to give it with such drugs. According to its own documents, dronedarone meets both criteria (posaconazole label and SmPC, FDA and EMA, and dronedarone SmPC, EMA). No document gives a waiting time between stopping posaconazole and starting dronedarone. The mean half-life of posaconazole tablets is 29 hours, and dronedarone and its metabolite are completely cleared from plasma 2 weeks after dronedarone is stopped (posaconazole and dronedarone SmPCs, EMA). If posaconazole has nevertheless been started during dronedarone treatment, stop dronedarone, as the SmPC requires whenever any contraindicated condition develops (dronedarone SmPC, EMA). Correct potassium and magnesium before starting dronedarone and keep them normal during treatment (dronedarone SmPC and label, EMA and FDA). With posaconazole, monitor potassium, magnesium and calcium and correct them as needed before and during treatment (posaconazole SmPC and label, EMA and FDA). Monitor the electrocardiogram (ECG) during dronedarone treatment and stop dronedarone if the heart-rate-corrected QT interval (QTc) reaches 500 ms or more (dronedarone SmPC, EMA). Use posaconazole with caution in congenital or acquired QTc prolongation, cardiomyopathy, especially with heart failure, sinus bradycardia and symptomatic arrhythmias (posaconazole SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Noxafil (posaconazole) prescribing information (2026)– FDA, DailyMed, Noxafil (Merck Sharp & Dohme), setid b073b082-7b57-4423-8c06-4fd4263d6f84, versión 56, revisión 02/2026, secciones 4.2, 4.3, 4.4, 4.5, 5.2 y 7.2
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Posaconazol (EU/1/05/320), sección 4.3 (2026)– EMA, Noxafil (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 105320002, consultada 10/2026, secciones 4.3, 4.4 y 4.5